Periodic Oxaliplatin Administration in Synergy with PER2‐Mediated PCNA Transcription Repression Promotes Chronochemotherapeutic Efficacy of OSCC. Issue 21 (8th September 2019)

• Record Type: Journal Article
• Authors: Tang, Qingming; Xie, Mengru; Yu, Shaoling; Zhou, Xin; Xie, Yanling; Chen, Guangjin; Guo, Fengyuan; Chen, Lili
• Is Part Of: Advanced science. Volume 6:Issue 21(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-09-08
• Subjects: chronochemotherapeutic strategy -- circadian clock genes -- DNA‐damaging repair -- oral squamous cell carcinoma -- oxaliplatin; Science -- Periodicals; 505
• DOI: 10.1002/advs.201900667
• Languages: English
• ISSNs: 2198-3844

Abstract

Abstract: Developing chemotherapeutic resistance affects clinical outcomes of oxaliplatin treatment on various types of cancer. Thus, it is imperative to explore alternative therapeutic strategies to improve the efficacy of oxaliplatin. Here, it is shown that circadian regulator period 2 (PER2) can potentiate the cytotoxicity of oxaliplatin and boost cell apoptosis by inhibiting DNA adducts repair in human oral squamous cell carcinoma (OSCC) cells. The circadian timing system is closely involved in controling the activity of DNA adducts repair and gives it a 24 h rhythm. The mechanistic dissection clarifies that PER2 can periodically suppress proliferating cell nuclear antigen ( PCNA ) transcription by pulling down circadian locomotor output cycles kaput–brain and muscle arnt‐like 1 heterodimer from PCNA promoter in a CRY1/2‐dependent manner, which subsequently impedes oxaliplatin‐induced DNA adducts repair. Similarly, PER2 is capable of improving the efficacy of classical DNA‐damaging chemotherapeutic agents. The tumor‐bearing mouse model displays PER2 can be deployed as an oxaliplatin administration timing biomarker. In summary, it is believed that the chronochemotherapeutic strategy matching PER2 expression rhythm can efficiently improve the oxaliplatin efficacy of OSCC. Abstract : Circadian regulator period 2 (PER2) potentiates the cytotoxicity of oxaliplatin depending on suppressing proliferating cell nuclear antigen ( PCNA ) transcription periodically by pulling down circadian locomotor output cycles kaput–brain and muscle arnt‐like 1 heterodimer from PCNA promoter in a CRY1/2‐dependent manner, which subsequently impedes oxaliplatin‐induced DNA adducts repair. Oxaliplatin administration in synergy with PER2 can efficiently improve chemotherapeutic efficacy of oral squamous cell carcinoma (OSCC).